Hulskof schreef op 28 januari 2024 10:37:
www.drugdiscoverynews.com/powering-up...Unlike T cells, which can survive for a person’s entire life, NK cells only have a one- to two-week lifespan in the body. They also tire quickly and lose their cancer-killing ability, allowing the tumor to relapse. Culturing NK cells or engineering them to express the cytokine IL-15 drives NK cell proliferation and persistence, and studies have shown that adding IL-15 increases NK cells’ effectiveness as a cancer cell therapy (3,4). But even with the addition of IL-15, subsets of patients still don’t respond to the treatment.
Kennelijk al langer bekend, dus Afmd / Artiva zullen wel hun redenen hebben om het niet te doen.